【结 构 式】 |
【分子编号】69007 【品名】(5-(tert-butyl)-1H-imidazol-4-yl)methanol 【CA登记号】 |
【 分 子 式 】C8H14N2O 【 分 子 量 】154.21204 【元素组成】C 62.31% H 9.15% N 18.17% O 10.37% |
与该中间体有关的原料药合成路线共 1 条
合成路线1
该中间体在本合成路线中的序号:(XI)The intermediate 5-tert-butylimidazole-4-carbaldehyde (III) is prepared by reaction of ethyl pivaloyl acetate (VII) with sulfuryl chloride in chloroform to provide the 2-chloro derivative (VIII), which is cyclized with formamide (IX) in the presence of a trace of water in a sealed tube at 150 oC, affording ethyl 5-tert-butylimidazole-4-carboxylate (X). Reduction of ester (X) with LiAlH4 in THF gives alcohol (XI), which is finally oxidized to the target carbaldehyde (III) using MnO2 in acetone .
【1】 Hayashi, Y., Grodberg, J., Palladino, M. (Nereus Pharmaceuticals, Inc). Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins dehydrophenylahistins and analogs thereof. EP 1529044, JP 2006511534, WO 2004054498. |
【2】 Palladino, M.A., Lloyd, G.K., Hayashi, Y., Nicholson, B. (Nereus Pharmaceuticals, Inc). Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof. EP 1711487, JP 2007520565, WO 2005077940. |
【3】 Palladino, M., Lloyd, G.K., Hayashi, Y. (Nereus Pharmaceuticals, Inc). Analogs of dehydrophenylahistins and their therapeutic use. EP 1926724, US 2007078138, WO 2007035841. |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(III) | 69002 | 5-tert-butylimidazole-4-carbaldehyde;5-(1,1-dimethylethyl)-1H-Imidazole-4-carboxaldehyde;4-(1,1-dimethylethyl)-1H-Imidazole-5-carboxaldehyde | 714273-83-3 | C8H12N2O | 详情 | 详情 |
(VII) | 69004 | ethyl 4,4-dimethyl-3-oxopentanoate;Ethyl pivaloylacetate | 17094-34-7 | C9H16O3 | 详情 | 详情 |
(VIII) | 69005 | ethyl 2-chloro-4,4-dimethyl-3-oxopentanoate | C9H15ClO3 | 详情 | 详情 | |
(IX) | 16598 | Formamide | 75-12-7 | CH3NO | 详情 | 详情 |
(X) | 69006 | ethyl 5-(tert-butyl)-1H-imidazole-4-carboxylate | C10H16N2O2 | 详情 | 详情 | |
(XI) | 69007 | (5-(tert-butyl)-1H-imidazol-4-yl)methanol | C8H14N2O | 详情 | 详情 |
Extended Information